American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

Related news

BDSXBiodesix2026-10-19 10:00 EST

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

BDSXBiodesix2026-10-13 10:00 EST

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

BIAFbioAffinity Technologies, Inc.2026-07-27 12:08 EST

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-10-15 12:00 EST

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

RHHBYRoche Holdings AG2026-10-10 21:40 EST

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

View all latest news

Biodesix

Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations. Diagnostic Testing The company provides blood-based and...